ASD Phenotype 1 Identification via Nrf2-Activator Response
Solution Overview
Problem
Current diagnostic methods for autism spectrum disorder (ASD) are inadequate in efficiently identifying subgroups with distinct genetic and molecular causes, limiting the effectiveness of targeted pharmacological therapies.
Innovation Solution
Administering an Nrf2-activator, such as sulforaphane, to ASD patients and identifying ASD phenotype 1 patients based on their negative response, which involves worsening of symptoms, to characterize specific subgroups for tailored treatment approaches.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If behavioral based diagnostic approaches are used for ASD, then diagnostic coverage is broad, but molecular and genetic classification precision is poor
Solution Approach 1:
The patent segments the homogeneous ASD diagnostic category into distinct molecular and genetic subtypes. By applying pharmacological challenges with Nrf2-activators and measuring specific biomarker responses, the method divides patients into subgroups based on their molecular phenotype, thereby improving classification precision while maintaining broad diagnostic coverage through the systematic evaluation of multiple molecular pathways.
Solution Approach 2:
The patent applies local quality by focusing on specific molecular and genetic characteristics within the broader ASD population. Rather than using a uniform diagnostic approach, the method identifies and measures specific biomarkers (such as Nrf2 pathway activity, oxidative stress markers, and genetic variants) in different patient subgroups, allowing for precise molecular classification tailored to each patient's underlying pathology.
2Measurement precision
If genetic screening methods are used to identify ASD subgroups, then molecular classification accuracy improves, but diagnostic efficiency and time consumption increase
Solution Approach 1:
The patent applies preliminary action by first conducting broad behavioral screening to identify potential ASD cases, then selectively applying molecular and genetic testing only to those patients who meet initial diagnostic criteria. This staged approach allows for efficient triage, reducing the number of patients who require time-consuming molecular analysis while maintaining high classification accuracy for those who are tested.
Solution Approach 2:
The patent utilizes parameter changes by measuring dynamic responses to pharmacological challenges (such as Nrf2-activator administration) rather than relying solely on static genetic markers. By monitoring changes in biomarker levels, behavioral symptoms, and physiological parameters over time during and after drug administration, the method achieves high molecular classification accuracy through functional assessment that can be completed more efficiently than comprehensive genomic sequencing.
3Measurement precision
If comprehensive molecular and genetic testing is performed on all ASD patients, then subtype identification accuracy improves, but cost and resource requirements increase
Solution Approach 1:
The patent segments the comprehensive testing approach into targeted molecular assays based on suspected phenotypic subgroups. Rather than performing all possible genetic and molecular tests on every patient, the method divides testing into specific panels tailored to different molecular phenotypes (such as oxidative stress pathways, neurotransmitter systems, or specific genetic syndromes), reducing overall resource requirements while maintaining high subtype identification accuracy through focused evaluation.
Solution Approach 2:
The patent uses copying by developing and validating simplified biomarker assays that replicate the information obtained from more complex and expensive genomic analyses. By creating surrogate markers (such as blood-based oxidative stress markers that reflect mitochondrial function, or inflammatory cytokine profiles that indicate immune activation), the method achieves accurate molecular subtype classification at lower cost and with fewer resources than comprehensive whole-genome sequencing or multiple specialized tests.
Data Source
AI summary
The present invention is directed to a method of identifying autism spectrum disorder (ASD) phenotype 1 patients, wherein the method comprises: administering an Nrf2-activator to an ASD patient previously diagnosed with idiopathic ASD or a subject displaying clinical signs of ASD, and identifying the ASD patient as an ASD phenotype 1 patient if the patient shows a negative response after administration of the Nrf2-activator. Likewise, the present invention is directed to a method for classifying autism spectrum disorder (ASD) phenotype 1 patients, the method comprising: administering an Nrf2-activator to a subject, and observing if the subject shows a negative response after administration of the Nrf2-activator, in which the subject is a patient previously diagnosed with idiopathic ASD or a subject displaying clinical signs of ASD and in which the negative response supports classification of the subject as an ASD phenotype 1 patient.